Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization
Background COVID-19 patients present with delirium during their hospitalization. Aims To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. Methods COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. Results Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Discussion The use of LMWH was associated with absence of delirium, independently of comorbidities and age. Conclusions The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Neurological sciences - 42(2020), 4 vom: 13. Nov., Seite 1527-1530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
D’Ardes, Damiano [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
C reactive protein |
| Anmerkungen: |
© Fondazione Società Italiana di Neurologia 2020 |
|---|
| doi: |
10.1007/s10072-020-04887-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2124360272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2124360272 | ||
| 003 | DE-627 | ||
| 005 | 20230505085614.0 | ||
| 007 | tu | ||
| 008 | 230505s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-020-04887-4 |2 doi | |
| 035 | |a (DE-627)OLC2124360272 | ||
| 035 | |a (DE-He213)s10072-020-04887-4-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90$jNeurologie |2 bkl | ||
| 100 | 1 | |a D’Ardes, Damiano |e verfasserin |0 (orcid)0000-0001-5573-4536 |4 aut | |
| 245 | 1 | 0 | |a Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Fondazione Società Italiana di Neurologia 2020 | ||
| 520 | |a Background COVID-19 patients present with delirium during their hospitalization. Aims To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors. Methods COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales. Results Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006). Discussion The use of LMWH was associated with absence of delirium, independently of comorbidities and age. Conclusions The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae. | ||
| 650 | 4 | |a Delirium | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Low molecular weight heparin | |
| 650 | 4 | |a C reactive protein | |
| 700 | 1 | |a Carrarini, Claudia |0 (orcid)0000-0003-0718-9929 |4 aut | |
| 700 | 1 | |a Russo, Mirella |0 (orcid)0000-0002-9937-5923 |4 aut | |
| 700 | 1 | |a Dono, Fedele |0 (orcid)0000-0003-3575-2942 |4 aut | |
| 700 | 1 | |a Speranza, Rino |4 aut | |
| 700 | 1 | |a Digiovanni, Anna |4 aut | |
| 700 | 1 | |a Martinotti, Giovanni |0 (orcid)0000-0002-7292-2341 |4 aut | |
| 700 | 1 | |a Di Iorio, Angelo |0 (orcid)0000-0003-2899-146X |4 aut | |
| 700 | 1 | |a Onofrj, Marco |0 (orcid)0000-0002-0480-2495 |4 aut | |
| 700 | 1 | |a Cipollone, Francesco |0 (orcid)0000-0002-5993-9341 |4 aut | |
| 700 | 1 | |a Bonanni, Laura |0 (orcid)0000-0001-7443-9233 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Springer International Publishing, 1999 |g 42(2020), 4 vom: 13. Nov., Seite 1527-1530 |w (DE-627)320571521 |w (DE-600)2016546-8 |x 1590-1874 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2020 |g number:4 |g day:13 |g month:11 |g pages:1527-1530 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10072-020-04887-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PSY | ||
| 936 | b | k | |a 44.90$jNeurologie |q VZ |0 106409980 |0 (DE-625)106409980 |
| 951 | |a AR | ||
| 952 | |d 42 |j 2020 |e 4 |b 13 |c 11 |h 1527-1530 | ||